ClinicalTrials.gg
RecruitingNCT06349408Updated Sep 25, 2026

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of IBI3001 in Locally Advanced Solid Tumor, sponsored by Fortvita Biologics (USA)Inc.. Recruiting at 27 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Fortvita Biologics (USA)Inc. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Sep 25, 2026First site in United StatesSponsor changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

02

Conditions studied

  • Locally Advanced Solid Tumor
03

In context

Lead sponsor

Fortvita Biologics (USA)Inc. is the lead sponsor of 5 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female participants ≥ 18 years old;
  2. Has an (ECOG) performance status (PS) of 0 or 1;
  3. Has an anticipated of ≥ 12 weeks;
  4. Adequate bone marrow and organ function:
  5. At least 1 evaluable lesion according to (RECIST) Version 1.1. for dose escalation , and 1 for dose expansion.
  6. Has a documented (- or cytologically-proven), unresectable, locally advanced or solid tumor that is to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.

Key Exclusion Criteria:

  1. Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
  2. Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
  3. Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
  4. Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
  5. Known symptomatic central nervous system (CNS) metastases.
  6. History of pneumonia requiring therapy, or history of lung diseases; Uncontrolled diseases;
  7. History of endotracheal or gastrointestinal stent implantation;
  8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
  9. Esophageal or gastric varices requiring immediate intervention;
  10. Not eligible to participate in this study at the discretion of the investigator;
  11. Do not have adequate treatment before study drug administration. -
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Open-label: IBI3001 monotherapy

    Drug: IBI3001

Interventions

  • DrugIBI3001

    The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV)

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events

    Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria

    Time frame: 24 months

  2. Number of subjects with clinically significant changes in physical examination results

    Clinically significant abnormal physical examination findings reported by the investigator.

    Time frame: 24 months

  3. Number of subjects with clinically significant changes in vital signs

    Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

    Time frame: 24 months

  4. MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)

    Dose limiting toxicity (DLT) to establish MTD or RP2D

    Time frame: 24 months

Secondary outcomes

  1. Plasma concentration (Cmax) of IBI3001

    Plasma concentration of IBI3001 for single and multiple doses.

    Time frame: 24 months

  2. Area under the curve (AUC) of IBI3001

    AUC of IBI3001 for single and multiple doses

    Time frame: 24 months

  3. Time to maximum concentration (Tmax) of IBI3001

    Tmax of IBI3001 for single and multiple doses.

    Time frame: 24 months

  4. Clearance (CL) of IBI3001

    Clearance of IBI3001 from the plasma

    Time frame: 24 months

  5. Volume of distribution (V) of IBI3001

    Apparent volume of distribution of IBI3001

    Time frame: 24 months

  6. Half-life (T1/2) of IBI3001

    T1/2 of IBI3001 for single and multiple doses

    Time frame: 24 months

  7. Immunogenicity of IBI3001

    Incidence of anti-drug (IBI3001) antibody

    Time frame: 24 months

  8. Objective response rate (ORR)

    ORR as evaluated per the RECIST v1.1 criteria

    Time frame: 24 months

  9. Duration of response (DoR)

    DoR as evaluated per the RECIST v1.1 criteria

    Time frame: 24 months

  10. Disease control rate (DCR)

    DCR as evaluated per the RECIST v1.1 criteria

    Time frame: 24 months

  11. Time to response (TTR)

    TTR as evaluated per the RECIST v1.1 criteria

    Time frame: 24 months

  12. Progression free survival (PFS)

    PFS as evaluated per the RECIST v1.1 criteria

    Time frame: 24 months

  13. Overall survival (OS)

    Overall survival.

    Time frame: 24 months

07

Study locations

26 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2024
First posted
Apr 5, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
26 sites added, 4 sites removed — first site in United States
Show 26 added (21 China, 4 United States, 1 Australia)
  • START Center for Cancer Research · Los Angeles, United States
  • START Center for Cancer Research · East Brunswick, United States
  • NEXT Oncology · Dallas, United States
  • Virginia Cancer Specialists · Fairfax, United States
  • Wollongong Hospital · Wollongong, Australia
  • The First Affiliated Hospital of Anhui Medical University · Hefei, China
  • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
  • Chinese People's Liberation Army General Hospital · Beijing, China
  • First Affiliated Hospital, Fujian Medical University · Fuzhou, China
  • Fujian Cancer Hospital · Fuzhou, China
  • The Affiliated Tumor Hospital of Guangxi Medical University · Nanning, China
  • Harbin Medical University Cancer Hospital · Harbin, China
  • Anyang Cancer Hospital · Anyang, China
  • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
  • Henan Cancer Hospital · Zhengzhou, China
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, China
  • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
  • Xiangya Hospital, Central South University · Changsha, China
  • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University · Nanjing, China
  • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University) · Nanjing, China
  • Jiangxi Cancer Hospital · Nanchang, China
  • Shanghai East Hospital, Tongji University School of Medicine · Shanghai, China
  • Sichuan Cancer Hospital & Institute · Chengdu, China
  • West China Hospital, Sichuan University · Chengdu, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
  • Zhejiang Cancer Hospital · Hangzhou, China
Show 4 removed
  • Wollongong Public · Wollongong, Australia
  • Chinese PLA General Hospital · Beijing, China
  • Shanghai East Hospital · Shanghai, China
  • The First Affiliated Hospital of zhejiang University School of Medicine · Hangzhou, China
Sep 25, 2026
Contact
Study contact changed: s•••@innoventbio.com · •••3576→c•••@fortvitabio.com · •••0985; removed y•••@innoventbio.com · •••4992. See the current contact
Sep 25, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cancer Research SA · Adelaide, AustraliaContact v•••@crsa.au · •••2565→c•••@fortvitabio.com · •••0985
Sep 25, 2026
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.→Fortvita Biologics (USA)Inc.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    26 sites added, 4 sites removed — first site in United States
    Show 26 added (21 China, 4 United States, 1 Australia)
    • START Center for Cancer Research · Los Angeles, United States
    • START Center for Cancer Research · East Brunswick, United States
    • NEXT Oncology · Dallas, United States
    • Virginia Cancer Specialists · Fairfax, United States
    • Wollongong Hospital · Wollongong, Australia
    • The First Affiliated Hospital of Anhui Medical University · Hefei, China
    • Cancer Hospital, Chinese Academy of Medical Sciences · Beijing, China
    • Chinese People's Liberation Army General Hospital · Beijing, China
    • First Affiliated Hospital, Fujian Medical University · Fuzhou, China
    • Fujian Cancer Hospital · Fuzhou, China
    • The Affiliated Tumor Hospital of Guangxi Medical University · Nanning, China
    • Harbin Medical University Cancer Hospital · Harbin, China
    • Anyang Cancer Hospital · Anyang, China
    • The First Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    • Henan Cancer Hospital · Zhengzhou, China
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, China
    • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, China
    • Xiangya Hospital, Central South University · Changsha, China
    • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University · Nanjing, China
    • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University) · Nanjing, China
    • Jiangxi Cancer Hospital · Nanchang, China
    • Shanghai East Hospital, Tongji University School of Medicine · Shanghai, China
    • Sichuan Cancer Hospital & Institute · Chengdu, China
    • West China Hospital, Sichuan University · Chengdu, China
    • The First Affiliated Hospital, Zhejiang University School of Medicine · Hangzhou, China
    • Zhejiang Cancer Hospital · Hangzhou, China
    Show 4 removed
    • Wollongong Public · Wollongong, Australia
    • Chinese PLA General Hospital · Beijing, China
    • Shanghai East Hospital · Shanghai, China
    • The First Affiliated Hospital of zhejiang University School of Medicine · Hangzhou, China
    Sponsor Innovent Biologics (Suzhou) Co. Ltd.→Fortvita Biologics (USA)Inc.
    Contact Study contact changed: s•••@innoventbio.com · •••3576→c•••@fortvitabio.com · •••0985; removed y•••@innoventbio.com · •••4992. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cancer Research SA · Adelaide, AustraliaContact v•••@crsa.au · •••2565→c•••@fortvitabio.com · •••0985
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06349408
Responsible party
Sponsor
First posted
Apr 5, 2024
Start date
Jan 10, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Fortvita Biologics CT.gov Call Center
Contact
ct.govNotifications@fortvitabio.com
650-370-0985

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion